Latest Tophus Stories
New review outlines the data supporting the relationship between urate-lowering efficacy and the risk for infusion reactions with Krystexxa® (pegloticase), the only FDA-approved treatment for chronic
DALLAS, October 20, 2014 /PRNewswire/ -- ReportsnReports.com adds Gouty Arthritis (Gout) - Pipeline Review, H2 2014 market research report as well as EpiCast Report: Gout
Acquisition is highlighted by KRYSTEXXA® (pegloticase), the only product approved for the treatment of refractory chronic gout GLENDALE, Wis., Jan.
- Emitting flashes of light; glittering.